- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04486261
High-intensity Strength Training in Myositis (HI-STIM)
High-intensity Strength Training in Patients With Idiopathic Inflammatory Myopathies: Changes in Quality of Life, Muscle Strength, Function and Myocellular Parameters
Study Overview
Status
Intervention / Treatment
Detailed Description
Overall aim:
To investigate the effect of high-intensity strength training on quality of life, muscle strength, physical function, and disease activity in patients with myositis
Study design:
60 myositis patients will be included in a 16-week high-intensity strength training study. Patients will be randomly allocated into 2 groups (strength training and control) in a 1:1 ratio.
User involvement:
Myositis patients has been recruited to a patient advisory board. The advisory board's objective is to give patient-oriented project feedback, thus improving the overall research project.
Intervention:
Two training session per week for 16 weeks. Sessions consists of 3 sets of each exercise corresponding to 10 RM. Training progression will be accounted for and training loads will be evaluated weekly. The training protocol will be a full-body protocol, i.e. all major muscle groups will be engaged during each training session.
Outcomes:
The primary outcome is the Physical Component Summary Measure from the quality of life questionnaire (SF-36). Secondary outcomes include strength measures, functional tests, disease activity measures, questionnaires (e.g. International physical activity questionnaire), DEXA whole body scans, blood samples and muscle biopsies.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fulfilling the criteria for myositis by EULAR/ACR (Bottai et al., 2017; Lundberg et al., 2017)
- ≤ 5 mg/day Prednisolone
- Stable dosage of immunosuppressive treatment for at least 1 months prior to inclusion in the study
- Myositis diagnosis at least 6 months prior to inclusion in the study
Exclusion Criteria:
- Patients with sporadic inclusion body myositis and overlap myositis (myositis combined with another autoimmune rheumatic diseases, except Sjögren's Syndrome)
- Co-morbidity preventing resistance training (severe heart/lung-disease, uncontrolled hypertension (systolic > 160mmHg, diastolic > 100mmHg), severe knee/hip arthritis)
- Alcohol- and/or drug abuse. Defined by the guidelines issued by The Danish Health Authority
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-intensity strength training
16 weeks of high-intensity strength training two times per week. Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient) Interventions: Other: high-intensity strength training Drug: Usual care |
The high-intensity strength training protocol will consist of 2 training sessions per week.
The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM).
At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention.
The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
Other Names:
|
No Intervention: Control
Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient). Intervention: Drug: Usual care |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (health survey (SF-36) subscale: Physical Component Summary)
Time Frame: 16 weeks
|
Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Physical Component Summary.
The scale ranges from 0 to 100 where 100 is the highest score.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leg power
Time Frame: 16 weeks
|
Power rig
|
16 weeks
|
Handgrip strength
Time Frame: 16 weeks
|
Measured by a handheld dynamometer
|
16 weeks
|
Functional Index 3
Time Frame: 16 weeks
|
A test of muscle strength in a series of muscles, carried out by the physician or physiotherapist
|
16 weeks
|
30 seconds chair rise
Time Frame: 16 weeks
|
Participants are instructed to stand up and sit down on a chair as many times as possible in 30 sec.
|
16 weeks
|
Timed up-and-go
Time Frame: 16 weeks
|
Participants are instructed to rise from a chair walk 3 m forward, pass a marking and return to the chair and sit down as fast as possible
|
16 weeks
|
2-minute walk test
Time Frame: 16 weeks
|
A 2-min maximal walk test where the participant is encouraged to cover the greatest distance possible.
|
16 weeks
|
Balance
Time Frame: 16 weeks
|
Short physical performance battery - balance part
|
16 weeks
|
Whole-body, appendicular and lower-limb lean mass
Time Frame: 16 weeks
|
Measured by Dual-energy X-ray absorptiometry
|
16 weeks
|
Fat-free mass, body fat and total mass
Time Frame: 16 weeks
|
Measured by bioimpedance
|
16 weeks
|
Physician Global Activity
Time Frame: 16 weeks
|
Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity
|
16 weeks
|
Patient Global Activity
Time Frame: 16 weeks
|
Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity.
|
16 weeks
|
Extra-muscular Disease Activity
Time Frame: 16 weeks
|
An assessment tool used by the physician to evaluate disease activity in various organ systems via a scoring system and a 0-10 cm scale, where the higher score indicates higher disease activity.
|
16 weeks
|
Manual muscle test 8
Time Frame: 16 weeks
|
A test of muscle strength in a series of muscles, carried out by the physician
|
16 weeks
|
Health Assessment Questionnaire (HAQ)
Time Frame: 16 weeks
|
HAQ is a questionnaire to evaluate patient reported disability.
It has 8 categories with a range of questions.
Each question is scored from 0 to 3 where 0 is no disability and 3 is unable to do.
|
16 weeks
|
Physician Global assessment of disease damage
Time Frame: 16 weeks
|
Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage.
|
16 weeks
|
Patient Global assessment of disease damage
Time Frame: 16 weeks
|
Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage.
|
16 weeks
|
Medical history
Time Frame: 16 weeks
|
Questionnaire: Basic cardiovascular questionnaire concerning medical conditions, current medication, heart symptoms and smoking habits |
16 weeks
|
Self-perceived physical activity levels
Time Frame: 16 weeks
|
International Physical Activity Questionnaire - long
|
16 weeks
|
Quality of life (health survey (SF-36) subscale: Mental component summary)
Time Frame: 16 weeks
|
Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Mental Component Summary.
The scale ranges from 0 to 100 where 100 is the highest score.
|
16 weeks
|
Body mass index (BMI)
Time Frame: 16 weeks
|
Weight will be measured by scale (kg).
Height will be measured by measuring (m).
BMI will be derived from weight and height (kg/m^2)
|
16 weeks
|
Systolic and diastolic blood pressure
Time Frame: 16 weeks
|
Measured by blood pressure monitor
|
16 weeks
|
Blood samples (analysis of markers of af disease activity)
Time Frame: 16 weeks
|
Plasma analysis: lipid profile, HbA1c, troponins, NT-proBNP, creatine kinase
|
16 weeks
|
Electrocardiography (ECG)
Time Frame: 16 weeks
|
Standard 12-lead ECG at 25 mm/s is recorded and analyzed according to standard published criteria (48-50).
According to the Minnesota coding the PQ-interval is measured and presence of 1st, 2nd (including Mobitz type 1 and 2), and 3rd degree of AV block are noted.
Additional measures will include: P-wave duration (≥ 2.5 mm in any of leads II, III, aVF), QRS duration (≥ 120 ms in any of leads I, II, III, aVL, aVF), QTc duration (> 450 ms), atrial fibrillation and flutter.
|
16 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle biopsies
Time Frame: 16 weeks
|
Muscle biopsies will be taken on a selected number of subjects from either the vastus lateralis or the tibialis anterior muscle, for the use in future analysis of i.e. muscle fibre size and distribution, myogenic stem cell activity, capillary density, muscle inflammation ect.
|
16 weeks
|
Physical activity level
Time Frame: 16 weeks
|
Will be measured by activity tracker (watch)
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Louise Pyndt Diederichsen, PhD, Rigshospitalet, Denmark
Publications and helpful links
General Publications
- Bottai M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.
- Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum In: Arthritis Rheumatol. 2018 Sep;70(9):1532.
- Jensen KY, Aagaard P, Schroder HD, Suetta C, Nielsen JL, Boyle E, Diederichsen LP. High-intensity strength training in patients with idiopathic inflammatory myopathies: a randomised controlled trial protocol. BMJ Open. 2021 Jun 25;11(6):e043793. doi: 10.1136/bmjopen-2020-043793.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCT16072020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myositis
-
University of Kansas Medical CenterCompletedInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body MyositisUnited States
-
Institut National de la Santé Et de la Recherche...CompletedInclusion Body Myositis (IBM)France
-
La-ser Europe LimitedUnknownSporadic Inclusion Body Myositis
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body Myositis (sIBM)United States
-
Assistance Publique - Hôpitaux de ParisRecruitingInflammatory Myositis | Idiopathic Inflammatory Myositis | Drug-induced Inflammatory MyositisFrance
-
University of Southern DenmarkOdense University HospitalCompleted
-
University of Kansas Medical CenterBioSensicsRecruitingInclusion Body MyositisUnited States
-
Abcuro, Inc.Active, not recruitingInclusion Body MyositisAustralia
-
ZevraDenmarkUniversity College, London; University of Kansas Medical CenterTerminatedInclusion Body MyositisUnited States, United Kingdom
Clinical Trials on High-intensity strength training
-
Wake Forest UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Universita di VeronaUnknown
-
Norwegian School of Sport SciencesUppsala University; Haukeland University Hospital; University of Agder; Norwegian... and other collaboratorsCompleted
-
National Institute of Arthritis and Musculoskeletal...Completed
-
Norwegian University of Science and TechnologyCompleted
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
General Hospital Murska SobotaUniversity of Primorska; University of LjubljanaUnknownCoronary Artery Disease | Heart Failure With Reduced Ejection FractionSlovenia
-
Universidad de AlmeriaRecruiting
-
Linkoeping UniversityRegion Östergötland; Länssjukhuset i Kalmar länRecruitingHot Flashes | Postmenopausal SymptomsSweden
-
McMaster UniversityCompletedMobility Limitation | Fall Injury | Slip and FallCanada